Aristocrat Leisure up as investors look to July briefing after fresh buyback

Aristocrat Leisure up as investors look to July briefing after fresh buyback

June 14, 2026

Sydney, June 15, 2026, 04:02 AEST

  • Aristocrat Leisure finished the latest ASX session at A$53.91, gaining from A$53.38 the previous day. The wider S&P/ASX 200 index put on 1.98%.
  • Aristocrat Leisure Limited repurchased 124,895 shares on June 11, spending about A$6.65 million, according to its latest buy-back filing. Before that, the company had already bought back 23.57 million shares.
  • Aristocrat’s next big event is the July 1 investor briefing. The company will report full-year 2026 results on November 12.

Aristocrat Leisure Limited finished stronger, with shares up after the latest session as investors sized up a solid Australian market and more signs that the gaming tech group is sending money back to shareholders. The ASX stock closed at A$53.91 on June 12, up from A$53.38 the day before. Shares moved between A$53.53 and A$54.39 on volume near 1.81 million.

Aristocrat’s stock got backing from both a risk-on market and its own buy-back activity. The S&P/ASX 200 closed up 1.98% on Friday. Aristocrat’s June 12 filing showed it is still running an on-market buy-back, where it buys back shares off the market. Buy-backs can lift earnings per share if total earnings stay flat.

Aristocrat said in a filing it bought back 124,895 shares on June 11 for A$6.65 million. That’s after it had already repurchased 23.57 million shares in its buy-back program. The company kept its on-market buy-back open until May 12, 2027, and lifted the program limit to as much as A$2.5 billion.

Aristocrat’s recent buy-back comes after stronger first-half results out in May. The company posted normalised NPATA of A$794.0 million for the six months to March 31, which rose 8.4% in reported currency and 16.3% in constant currency. NPATA stands for net profit after tax before amortisation of acquired intangibles. Constant currency strips out FX moves. Revenue came in at A$3.03 billion, slipping 0.2% on a reported basis but climbing 6.4% in constant currency. “A strong first half, with clear progress across the business and market share gains in key segments,” CEO Trevor Croker said.

Aristocrat’s bull case rests on market-share gains in its core land-based gaming, steady buybacks, and digital growth through Aristocrat Interactive. The company reported Aristocrat Gaming revenue up at A$1.96 billion for the first half. Product Madness social casino revenue came in 4.7% higher at US$541.7 million. Aristocrat Interactive rose 6.5% to US$230.3 million.

Bears say the growth story isn’t locked in yet. Product Madness revenue slid 4.1% after Aristocrat sold its Social Casual unit, and Aristocrat Interactive profit is down 10.6% as the firm put more money into recent buys and left White Label. Those valuation details count—the market is paying up for real earnings growth, not just capital returns.

Analysts are still positive, though there is some execution risk. MarketScreener reports 17 analysts with a mean “buy” call. The average target price comes in at A$63.04, lowest at A$59.10, while shares last closed at A$53.91. On these numbers, the stock isn’t outright cheap but may have appeal for some. The buy-back and earnings have the potential to lift the shares, but valuation will come down to Aristocrat hitting full-year NPATA and stronger Interactive returns. MarketScreener

Investors are looking to the July 1 investor briefing for updates on Aristocrat Gaming’s share gains, Product Madness’ direct-to-consumer sales, and progress toward Aristocrat Interactive’s FY29 US$1 billion revenue goal. The next big test comes with the full-year results on November 12, when the market will be checking if buy-back support lines up with earnings growth.

Stock Market Today

  • Telix Pharmaceuticals Stock Rises Ahead of Inclusion in STOXX Health Care Indices and Upcoming FDA Decisions
    June 14, 2026, 1:57 PM EDT. Telix Pharmaceuticals shares increased 0.97% to A$13.60 on June 15, 2026, as the company prepared for inclusion in the STOXX Asia/Pacific 600 Health Care and STOXX Global 1800 Health Care indices effective June 22. This index addition may attract passive investment but does not alter Telix's fundamentals. Regulatory catalysts loom, with the FDA action date for Pixclara set for September 11 and a Zircaix resubmission planned for H1 2026. Telix, specializing in radiopharmaceutical theranostics, posted a 11% revenue rise to US$230 million in Q1 2026 and maintains revenue guidance near US$950 million. Clinical progress in prostate cancer trials supports bullish sentiment amid a 45% year-on-year share price decline.